MedMira Completes Shipment of First Private Label Product



    Expands Usage of Patented Rapid Test Platform

    HALIFAX, Dec. 13 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that it has completed the initial shipment of its first
Private Label product to a distributor in Europe. Under this private label
agreement, Vitest GmbH of Hennigsdorf, Germany will be marketing and selling
the product, manufactured by MedMira, under the Vitest brand and as a part of
the Vitest suite of rapid testing products.
    With the successful patent grant in Europe for its core technology
platform earlier this year, MedMira had immediately begun to seek strategic
partners for which it would develop and manufacture rapid diagnostic products,
using its patented rapid flow-through testing technology. This recent shipment
is the first resulting from this new business development.
    "Our rapid flow-through technology platform has an endless list of
potential applications, for which our current product pipeline has barely
scratched the surface," said Hermes Chan, President and CEO of MedMira. "Our
strategic goals involve the pursuit of a wide range of opportunities to
diversify not only our own product portfolio, but also to make available a
private label/OEM capability to fill the needs of our partners. We are pleased
to welcome Vitest as our first partner in this endeavor."
    MedMira's patented core technology platform (European patent No. 1417489)
includes the innovative rapid flow-through diagnostic device, assay and
multi-functional buffer and is the basis for MedMira's newest generation of
infectious disease testing products - which are designed to deliver critical
answers when time really matters.

    About Vitest

    Vitest GmbH (www.vitest.de) is the German subsidiary of Vitest AG, a
privately held company based in Wollerau, Switzerland. Vitest is manufacturer
of medical rapid tests and known well for their high quality products. The
company provides doctors offices, clinics and government institutions with
innovative rapid tests. With the introduction of Vitest HIV to the German
market, Vitest takes the lead in the latest AIDS prevention movement to reduce
the number of new HIV infections in Germany, by making better diagnostics more
widely available. For more information about Vitest, please contact Christiane
Ewel, Head of Marketing and Sales (ch.ewel@vitest.de), Vitest GmbH, D -16761
Hennigsdorf, Neuendorfstra. 24b, Tel. +49 3302 202 7100,
Fax. +49 3302 202 7199

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, ir@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890